<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210804052079N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-06-02</date_registration>
      <primary_sponsor>Cognitive Sciences and Technologies Council</primary_sponsor>
      <public_title>The Effect of Episodic Future Thinking (EFT) on Craving</public_title>
      <acronym>CIREF</acronym>
      <scientific_title>The Effect of Cue-Exposure Combined with Episodic Future Thinking (CIREF) Intervention on Craving and Delay Discounting in Opioid Users Receiving Methadone Maintenance Treatment: A Pilot Study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-06-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>28</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63846</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Other design features: In the present study, an intervention called " Intervention based on Episodic Future Thinking (EFT)" has been designed for the first time. It consists of 4 one-hour sessions. The protocol tries to be feasible and led participants to remain in the study. The set of opioid narrative cues, applied in the intervention have been completely personalized, Randomization description: After screening, participants meeting the required inclusion criteria will be randomly allocated to the intervention and the active control group through block randomization. The randomization list will be created using Python. In block randomization, there would be only six conditions in which two cells get “C” control and two cells get “T” trial for a block of four cells. As a result, the 6 outcomes will be as follows: 1: CCTT, 2: TTCC, 3: CTCT, 4: TCTC, 5: TCCT, 6: CTTC. Also, a number will be randomly assigned to each participant, Blinding description: In the present study, after screening and randomization, individuals will be officially included in the study. In the first session of the intervention, a brief description of the study process by the examiner will be provided to the participant. They will then be given an informed consent form. The information contained in the informed consent form and how to spend the study will be fully explained to the participants. In the process of conducting the study, participants will be blind to the intervention received. It should be noted that the staff present at the outpatient clinic will be blind to the whole intervention process. These people are: nurse, psychologist, assistant and also the technical manager of the clinic. All data recorded during the intervention sessions will be stored in the computer of the outpatient clinic (the venue of the intervention sessions) in an encrypted folder that only the researcher has access to, and will be deleted after the intervention and follow-up sessions. At the end of the intervention sessions, only the data obtained from the questionnaires will be provided to the data analyzer.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Opioid Substance Use.</hc_freetext>
      <i_freetext>Intervention 1: Trial group: Episodic Future thinking group: In the first session, the subjects of the intervention group will be asked to generate the opioid-related cues for the the following for the next 6 time intervals, including: 1 day, 1 week, 1 month, 3 months, 6 months and 1 year in future. Subjects will then scored them in terms of Valence, arousal, and vividness.Momentary craving, craving in the past period and the delay discounting will be  measured. Next, the subject will be shown the cues of the relevant time intervals on the screen. In the first stage of the Episodic Future thinking, the subject will be asked to simulate a possible future event in his/her mind based on the related cue. In the second stage, he will be asked to predict all the details of the event in 2-3 minutes. The drug-related cues will trigger the drug-related memories which cause in negative retrieval. In the third stage, the subject's memory will be fragile and vulnerable due to stimulation. Now the person will be asked to think about the consequences of substance abuse and form a new interpretation and pursue this interpretation as a goal in his mind. This goal is actually a kind of new memory that is created in a person's mind called reappraisal. In the fourth step, the subject will be asked to plan small but strong steps to achieve the leading plan. These small steps will help him to have a predetermined plan to achieve his goal and also be able to manage his craving toward drug cues. After the intervention sessions, momentary craving, craving in the past period and delay discounting will be measured again. Intervention 2: Control group: Control group: Episodic Recent thinking group: In the first session, the subjects of the intervention group will be asked to generate the opioid-related cues for the the following for the next 6 time intervals, including: 1,3,5,7,9 days in the past. Subjects will then scored them in terms of Valence, arousal, and vividness.Momentary craving, craving in the past period and the delay discounting will be  measured. Next, the subject will be shown the cues of the relevant time intervals on the screen. In the first stage of the Episodic Recent thinking, the subject will be asked to simulate a possible event in the recent past based on the related cue. In the second stage, he will be asked to predict all the details of the event in 2-3 minutes. Now the person will be asked to set a new goal toward the drug-related cue. In the fourth step, the subject will be asked to plan small steps to achieve the leading goal. After the intervention sessions, momentary craving, craving in the past period and delay discounting will be measured again.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Matin Toulami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.7, Sheibani Alley, North Jamalzadeh St., West Keshavarz Blvd.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1418643514</zip>
        <telephone>+98 21 6642 6816</telephone>
        <email>matin.toulami08@gmail.com</email>
        <affiliation>Institute for Cognitive Science Studies</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Tara Rezapour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Institute for Cognitive Science Studies, Cognitive Science Blvd.</address>
        <city>Pardis</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1658344575</zip>
        <telephone>+98 21 7629 1130</telephone>
        <email>tara_rezapour@yahoo.com</email>
        <affiliation>Institute for Cognitive Science Studies</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>History of Opioid Use
Methadone Maintenance Treatment Receivers
Ability to Read and Write</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>45 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Chronic Mental Disorder History</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F11</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Opioid related disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Behavior</i_code>
      <i_code>Behavior</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Trial group: Episodic Future thinking group: In the first session, the subjects of the intervention group will be asked to generate the opioid-related cues for the the following for the next 6 time intervals, including: 1 day, 1 week, 1 month, 3 months, 6 months and 1 year in future. Subjects will then scored them in terms of Valence, arousal, and vividness.Momentary craving, craving in the past period and the delay discounting will be  measured. Next, the subject will be shown the cues of the relevant time intervals on the screen. In the first stage of the Episodic Future thinking, the subject will be asked to simulate a possible future event in his/her mind based on the related cue. In the second stage, he will be asked to predict all the details of the event in 2-3 minutes. The drug-related cues will trigger the drug-related memories which cause in negative retrieval. In the third stage, the subject's memory will be fragile and vulnerable due to stimulation. Now the person will be asked to think about the consequences of substance abuse and form a new interpretation and pursue this interpretation as a goal in his mind. This goal is actually a kind of new memory that is created in a person's mind called reappraisal. In the fourth step, the subject will be asked to plan small but strong steps to achieve the leading plan. These small steps will help him to have a predetermined plan to achieve his goal and also be able to manage his craving toward drug cues. After the intervention sessions, momentary craving, craving in the past period and delay discounting will be measured again.</i_keyword>
      <i_keyword>Control group: Control group: Episodic Recent thinking group: In the first session, the subjects of the intervention group will be asked to generate the opioid-related cues for the the following for the next 6 time intervals, including: 1,3,5,7,9 days in the past. Subjects will then scored them in terms of Valence, arousal, and vividness.Momentary craving, craving in the past period and the delay discounting will be  measured. Next, the subject will be shown the cues of the relevant time intervals on the screen. In the first stage of the Episodic Recent thinking, the subject will be asked to simulate a possible event in the recent past based on the related cue. In the second stage, he will be asked to predict all the details of the event in 2-3 minutes. Now the person will be asked to set a new goal toward the drug-related cue. In the fourth step, the subject will be asked to plan small steps to achieve the leading goal. After the intervention sessions, momentary craving, craving in the past period and delay discounting will be measured again.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The primary outcome measure of the present study will be momentary craving assessed by the score of 3 sub-scales of the Desire for Drug Questionnaire. The sub-scales including:  questions 1, 2, 4, 6, 7, 10, 13, 14 investigate the patient’s “desire and intention to drug use”, questions 5, 9, 11, 12 investigate the “negative reinforcement for drug use" and questions 3 and 8 which are related to “drug abuse control”. There is no normal score for this questionnaire and the significance level of change is the evaluation criterion. Score received in each sub-scales will be assessed at baseline and after intervention. Timepoint: Baseline and after 4-week interventions. Method of measurement: 14-item Desire for Drug Questionnaire by Franken et al. will be used to assess the momentary craving.</prim_outcome>
      <prim_outcome>The primary outcome measure of the present study will be craving in the past period assessed by the score of 4 sub-scales of Obsessive Compulsive Drug Use Scale. The sub-scales including: questions 1, 2, 7, 8 investigate “desire and mental preoccupation with drugs”, questions  3 and 9 could be called as “the effect of desire for drug, and drug-related thoughts on the patient’s work and life”, questions 4, 6, 11 and 12 are related to “motivation, emotion, and lack of control” and questions 5 and 10 evaluate “resistance to drug use”. score for this questionnaire and the significance level of change is the evaluation criterion. Score received in each sub-scales will be assessed at baseline and after intervention. Timepoint: Baseline and after 4-week interventions. Method of measurement: 10-item Obsessive Compulsive Drug Use Scale by Franken et al. will be used to assess the craving in the past period.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The secondary outcome of the present study is the score obtained in the dual monetary selection questionnaire. Timepoint: At baseline and after 4-weeks of intervention. Method of measurement: Delay Discounting will be assessed by Monetary Choice Questionnaire.Monetary Choice Questionnaires is a 27-item, brief dichotomous choice tasks that assess preference between small immediate and larger delayed monetary outcomes.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Cognitive Sciences and Technologies Council</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-10-04</approval_date>
        <contact_name>Research Ethics Committees of Institute for cognitive science studies</contact_name>
        <contact_address>Institute for Cognitive Science Studies, Cognitive Science Blvd, Pardis Pardis Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
